Search research articles
Contact Us
Filters
Showing results (201-210 of 237) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
Social influences on clinical outcomes of patients with ovarian cancer
Susan K Lutgendorf, Koen De Geest, David Bender, et al.
Brain, Behavior, and Immunity
|
August 14, 2012
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability
Andrew Schrepf, Lauren Clevenger, Desire Christensen, et al.
Gynecologic Oncology
|
July 30, 2019
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression
Lois M Ramondetta, Wei Hu, Premal H Thaker, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
International Journal of Cancer
|
December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cells
Whitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
P H Thaker, R Salani, W E Brady, et al.
Molecular Cancer Therapeutics
|
May 19, 2022
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Shaina F Bruce, Kevin Cho, Hollie Noia, et al.
Cancer Research
|
November 3, 2007
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer
Charles N Landen, Yvonne G Lin, Guillermo N Armaiz Pena, et al.
Gynecologic Oncology
|
July 6, 2024
A toolkit for a modern gynecologic oncology tissue bank
Olivia Graham, Jeimmy Rodriguez, Rachel Abbott, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 237) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
Social influences on clinical outcomes of patients with ovarian cancer
Susan K Lutgendorf, Koen De Geest, David Bender, et al.
Brain, Behavior, and Immunity
|
August 14, 2012
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability
Andrew Schrepf, Lauren Clevenger, Desire Christensen, et al.
Gynecologic Oncology
|
July 30, 2019
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression
Lois M Ramondetta, Wei Hu, Premal H Thaker, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
International Journal of Cancer
|
December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cells
Whitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
P H Thaker, R Salani, W E Brady, et al.
Molecular Cancer Therapeutics
|
May 19, 2022
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Shaina F Bruce, Kevin Cho, Hollie Noia, et al.
Cancer Research
|
November 3, 2007
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer
Charles N Landen, Yvonne G Lin, Guillermo N Armaiz Pena, et al.
Gynecologic Oncology
|
July 6, 2024
A toolkit for a modern gynecologic oncology tissue bank
Olivia Graham, Jeimmy Rodriguez, Rachel Abbott, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Page
of 24